Skip to main content

Table 3 Demographics and baseline characteristics (ITT, N = 19)

From: Efficacy of combining intravitreal injections of ranibizumab with micropulse diode laser versus intravitreal injections of ranibizumab alone in diabetic macular edema (ReCaLL): a single center, randomised, controlled, non-inferiority clinical trial

Variable

 

IVOM-Group

(N = 9)

IVOM + Laser-Group(N = 10)

Total

(N = 19)

p-valuea

Age (years)

Mean ± SD

70.78 ± 8.96

70.70 ± 7.60

70.74 ± 8.03

0.984

Gender

 Male

N (%)

6 (66.7%)

8 (80.0%)

14 (73.7%)

 

 Female

N (%)

3 (33.3%)

2 (20.0%)

5 (26.3%)

 

Race

 White

N (%)

9 (100%)

10 (100%)

19 (100%)

 

Weight (kg)

Mean ± SD

92.83 ± 8.15

83.90 ± 12.92

88.13 ± 11.58

0.093

Height (cm)

Mean ± SD

173 ± 12

173 ± 8

173 ± 10

0.860

BMI (kg/m2)

Mean ± SD

31.13 ± 3.71

28.04 ± 2.38

29.51 ± 3.38

0.043

Diastolic blood pressure (mmHg)

Mean ± SD

82.13 ± 13.16

80.40 ± 9.38

81.17 ± 10.90

0.750

Systolic blood pressure (mmHg)

Mean ± SD

147.0 ± 14.22

151.1 ± 10.91

149.3 ± 12.28

0.498

HbA1c (%)

Mean ± SD

7.54 ± 1.51

6.80 ± 0.85

7.19 ± 1.26

0.274

Study eye

 Left

N (%)

7 (77.8%)

5 (50%)

12 (63.2%)

 

 Right

N (%)

2 (22.2%)

5 (50%)

7 (36.8%)

 

BCVA

Mean

20/120

20/95

20/110

0.478

CMT (μm)

Mean ± SD

485 ± 170

434 ± 118

458 ± 143

0.456

  1. ITT intent-to-treat set (all randomized subjects); BMI body mass index; BCVA best corrected visual acuity; CMT central macular thickness;
  2. acomparisons between groups were done using Student’s t-test for independent variables